This report was first published by Endpoints News. To see the original version, click here
The FDA said Friday it has issued new fast-track vouchers to three psychedelic companies, and its selections have come as a “surprise” to Wall Street.
In an unusual move, the agency didn’t name the sponsors or their programs in its announcement, but said the Commissioner’s National Priority Vouchers are going toward companies that are advancing psilocybin for treatment-resistant depression, methylone for post-traumatic stress disorder and psilocybin for major depressive disorder.
您已阅读19%（573字），剩余81%（2416字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。